Bactiguard Holding AB represents a strong set of values and a clear corporate philosophy. The company is committed to improving patient safety and reducing the risk of healthcare-associated infections. Bactiguard focuses on preventing the spread of infections through their innovative and sustainable solutions, such as the Bactiguard Infection Protection (BIP) technology. With a dedication to continuous research and development, Bactiguard aims to provide healthcare professionals and patients with reliable and effective infection prevention products. By prioritizing patient well-being and safety, Bactiguard Holding AB establishes itself as a trusted and responsible player in the healthcare industry.

Bactiguard Holding AB is primarily present in various countries and regions globally. With a strong global presence, the company operates in Europe, Asia, the Middle East, and South America, among other regions. Bactiguard Holding AB's products and solutions are available in countries such as Sweden, Germany, China, India, Saudi Arabia, Brazil, and many others. The company's extensive international reach allows it to serve a diverse range of markets, ensuring the broad distribution and accessibility of its innovative healthcare solutions worldwide.

Bactiguard Holding AB, a leading healthcare company, has achieved several significant milestones throughout its journey. The company has successfully developed and commercialized its innovative infection prevention solutions, creating a positive impact on the global healthcare industry. Bactiguard has expanded its reach by establishing strategic partnerships with various renowned medical device companies, enabling its products to be widely available to healthcare providers and patients worldwide. The company's commitment to continuous research and development has led to the introduction of new and advanced technologies, further enhancing the efficacy of its infection prevention solutions. Bactiguard Holding AB continues to strengthen its position as a key player in the field of infection prevention, contributing to improved patient outcomes and reduced healthcare-associated infections.

Bactiguard Holding AB is a Swedish company with a rich history and background. Established in 2005, Bactiguard is dedicated to developing and providing infection prevention solutions. The company specializes in the development, production, and sale of unique coatings that prevent healthcare-associated infections. Bactiguard's innovative technology helps in reducing the use of antibiotics and creates safer healthcare environments for patients worldwide. With a strong commitment to research and development, Bactiguard continuously strives to enhance its products and expand its global presence. Through its sustainable and socially responsible approach, Bactiguard Holding AB remains a leading player in the infection prevention industry.

The main competitors of Bactiguard Holding AB in the market include companies such as 3M Health Care, C.R. Bard Inc., and Becton, Dickinson and Company (BD). These companies operate in the same market as Bactiguard Holding AB and offer similar medical device solutions aiming to prevent healthcare-associated infections. As a global leader in infection prevention, Bactiguard Holding AB competes through its unique and patented Bactiguard technology, providing antimicrobial coatings for medical devices. Its superior quality, innovative solutions, and strategic partnerships contribute to its competitive advantage in the industry.

Bactiguard Holding AB is primarily active in the healthcare industry.

The business model of Bactiguard Holding AB revolves around providing innovative infection prevention solutions. Bactiguard develops and markets medical devices coated with a unique and patented technology that reduces the risk of healthcare-associated infections. These devices include urinary catheters, endotracheal tubes, and other medical implants. By incorporating its effective and safe coating solution, Bactiguard aims to improve patient outcomes, reduce healthcare costs, and enhance overall patient safety. Bactiguard's commitment to research, development, and collaboration with healthcare providers contributes to its strong position in the global market as a trusted provider of infection prevention solutions.

Bactiguard Holding P/E suhe on −103,73.

Bactiguard Holding KUV on 8,77.

AlleAktien kvaliteediskoor ettevõttele Bactiguard Holding on 4/10.

oodatud Bactiguard Holding käive on 250,92 mln. SEK.

oodatud Bactiguard Holding kasum on −21,22 mln. SEK.

Bactiguard Holding AB is a Swedish company that manufactures medical devices and products that enhance protection against infections. Its business model is based on a unique technology that prevents the formation of biofilm on medical devices. Bactiguard's products are used in various areas such as intensive care, surgery, urology, and pediatrics. The company offers a wide range of products including catheters, bladder catheters, venous catheters, breathing tubes, gastric tubes, and many more. These products are designed to reduce the infection rate in clinical settings. Bactiguard's technology can be applied to various materials such as silicone, latex, PVC, or polyurethane. The company has three business areas: medical technology, licenses, and product development. In the medical technology segment, the company offers catheters and other devices coated with the unique Bactiguard technology. These products are sold either directly by Bactiguard or through its distribution partners. The licensing segment involves licensing the Bactiguard technology to other companies. The product development segment encompasses research and development of new products coated with the Bactiguard technology. Bactiguard's main markets are Europe, Asia, and North America. The company has distribution partners in more than 60 countries worldwide. Its key customers include hospitals, medical centers, and healthcare providers. Bactiguard has also formed partnerships with medical device manufacturers such as B. Braun and Hollister. The company's revenue is based on product sales and licensing. In 2019, the company earned EUR 56.2 million in revenue and had a profit of EUR 11.4 million. Bactiguard plans to expand its business in the future and explore new markets. It also intends to broaden its product range. To achieve its business goals, Bactiguard has developed a clear sustainability strategy. The company aims to reduce the medical demand for disposable plastics and promote the use of recyclable materials. It is also a member of the UN Global Compact initiative and is committed to achieving the United Nations' sustainability goals. In summary, Bactiguard offers medical devices and products coated with its unique Bactiguard technology. The company focuses on selling these products to medical facilities and licensing the technology to other companies. Bactiguard has a clear sustainability strategy and is committed to reducing environmental impact.

Bactiguard Holding maksab dividendi 0 SEK, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Bactiguard Holding jaoks arvutada või ettevõte ei maksa dividende välja.

Bactiguard Holding ISIN on SE0005878741.

Bactiguard Holding WKN on A115EQ.

Bactiguard Holding tähis on BACTI B.ST.

Viimase 12 kuu jooksul maksis Bactiguard Holding dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Bactiguard Holding tõenäoliselt dividendi summas 0 SEK.

Bactiguard Holding praegune dividenditootlus on .

Bactiguard Holding maksab kvartaalset dividendi. See makstakse välja kuudel .

Bactiguard Holding maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 SEK. See vastab dividenditootlusele 0 %.

Bactiguard Holding on liigitatud sektorisse 'Tervis'.

Viimase Bactiguard Holding dividendide saamiseks 19.9.2024 suuruses 0 SEK pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 19.9.2024.

Viimane dividendimakse toimus 19.9.2024.

Aastal 2023 maksis Bactiguard Holding 0 SEK dividende.

Bactiguard Holding dividendid makstakse välja SEK.